NTLA:NASDAQ
Intellia Therapeutics Inc
US$ 12,26
arrow_upward
+1,16%(+0,14) 1D
US$ 12,35
arrow_upward
+0,73% (+0,090)bedtimeNa sluitingstijd
Gesloten: 2 okt, 16:00:00 GMT-4 · USD
search
Alle symbolen
| Symbool | Prijs | Wijziging | Wijzigingspercentage |
|---|
insights_autoBelangrijkste inzichten voor NTLA genereren…
Openen
US$ 12,42
Hoog
US$ 12,76
Laag
US$ 12,10
Beursw.
1,72 mld.
Gem. vol.
4,03 mln.
Volume
4,50 mln.
52 wk hoog
US$ 28,24
52 wk laag
US$ 7,95
WPA
US$ -3,36
Bèta
1,80
Uitstaande aandelen
140,13 mln.
Aantal medewerkers
377
Openen
US$ 12,42
Hoog
US$ 12,76
Laag
US$ 12,10
Beursw.
1,72 mld.
Gem. vol.
4,03 mln.
Volume
4,50 mln.
52 wk hoog
US$ 28,24
52 wk laag
US$ 7,95
WPA
US$ -3,36
Bèta
1,80
Uitstaande aandelen
140,13 mln.
Aantal medewerkers
377
Nieuwsartikelen
Van webbronnen en nieuwspartners
Intellia Therapeutics
·
3 uur geleden
Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Simply Wall Street
·
1 dag geleden
Intellia Therapeutics (NTLA), What Is Drawing Fresh Attention Now?
Yahoo Finance
·
3 dagen geleden
Temporary Weakness in Intellia Stock Seems Like a Buying Opportunity
Profiel
Intellia Therapeutics, Inc. is an American clinical-stage biotechnology company focused on developing novel, potentially curative therapeutics leveraging CRISPR-based technologies. The company's in vivo programs use intravenously administered CRISPR as the therapy, in which the company's proprietary delivery technology enables highly precise editing of disease-causing genes directly within specific target tissues. Intellia's ex vivo programs use CRISPR to create the therapy by using engineered human cells to treat cancer and autoimmune diseases.
The CRISPR gene editing system was originally invented by Jennifer Doudna, one of Intellia's scientific founders, and Virginijus Šikšnys. The company has entered into a number of different research and development collaborations with leading and emerging biotechnology companies including Novartis, Regeneron, Avencell, SparingVision, Kyverna, and ONK Therapeutics.
Intellia has two in vivo programs in ongoing clinical trials. NTLA-2001 is an investigational CRISPR therapy candidate for the treatment for ATTR amyloidosis currently in Phase 1 studies. Wikipedia
Over Intellia Therapeutics Inc
CEOJohn Leonard
Medewerkers377
Opgericht2014
HoofdkantoorCambridge, Massachusetts, Verenigde Staten
Sector-
Websiteintelliatx.com